###begin article-title 0
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
VEGF T-1498C polymorphism, a predictive marker of differentiation of colorectal adenocarcinomas in Japanese
###end article-title 0
###begin p 1
Conflict of interest: The authors declare that no conflict of interest exists.
###end p 1
###begin p 2
###xml 24 29 24 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR1 </italic>
###xml 200 205 200 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"> VEGF</italic>
Background: Previously, MDR1 T-129C polymorphism, encoding multidrug resistant transporter MDR1/P-glycoprotein, was reported to be predictive of poorly-differentiated colorectal adenocarcinomas. Here, VEGF T-1498C, C-634G and C-7T polymorphisms, encoding vascular endothelial growth factor (VEGF), were investigated in terms of their association with differentiation grade.
###end p 2
###begin p 3
###xml 9 13 9 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 49 50 49 50 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</sup>
###xml 158 166 <span type="species:ncbi:9606">patients</span>
Methods: VEGF genotypes were determined by TaqManR MGB probe based polymerase chain reaction and evaluated were confirmed by direct sequencing in 36 Japanese patients.
###end p 3
###begin p 4
###xml 9 13 9 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
Results: VEGF T-1498C, but not C-634G or C-7T, was predictive of poorly-differentiated ones, and thereby a poor prognosis (p = 0.064 for genotype, p = 0.037 for allele), and this effect can be explained by that on VEGF expression. Treatment of a colorectal adenocarcinoma cell line, HCT-15, with sodium butyrate, a typical differentiating agent, resulted in an increase of alkaline phosphatase activity and MDR1 mRNA expression, but in a decrease of VEGF mRNA expression. The transfection of VEGF small interfering RNA (siRNA) induced the expression of MDR1 mRNA to 288-332% of the control level, whereas MDR1 siRNA had no effect on VEGF mRNA expression.
###end p 4
###begin p 5
###xml 13 17 13 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 180 188 <span type="species:ncbi:9606">patients</span>
Conclusions: VEGF T-1498C polymorphism is also a candidate marker predictive of poorly-differentiated colorectal adenocarcinomas, but further investigations with a large number of patients should be addressed to draw a conclusion.
###end p 5
###begin title 6
1. Introduction
###end title 6
###begin p 7
###xml 201 202 201 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 472 473 472 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 475 476 475 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 502 503 502 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 896 897 896 897 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 899 900 899 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 1183 1184 1183 1184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 1232 1233 1232 1233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
Numerous clinicopathological factors have been reported to have prognostic significance for colorectal cancer, including tumor invasion, nodal metastasis, differentiation, and lymphocytic infiltration 1. The importance of differentiation was already suggested in the 1920s, and the tumors have been graded into well-, moderately- and poorly-differentiated types. Most of colorectal cancers are assessed as well- or moderately-differentiated adenocarcinoma in the Japanese 2, 3; that is, Takeuchi et al.3 reported poorly-, moderately- and well-differentiation types were found at 3.3%, 77.2% and 19.5% in adenocarcinomas, respectively. The 5-year survival rate depended on the differentiation grade, and for well-differentiated types was reported to be 71-72%, but in contrast, it was only 32-46% for poorly-differentiated adenocarcinoma in Japanese, although we have rarely encountered this type 2, 3. Thus, it is important to evaluate differentiation grade accurately to decide a management strategy; however, its usefulness is sometimes thought to be limited due to difficulties in assessment and thereby reproducibility, encouraging us to search for alternative molecular markers 4, or to establish a method of subclassification 3.
###end p 7
###begin p 8
###xml 218 219 218 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 220 221 220 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 495 499 495 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 1154 1155 1154 1155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 1283 1287 1283 1287 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR1</italic>
###xml 1417 1418 1417 1418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 1456 1460 1456 1460 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR1</italic>
###xml 1690 1691 1690 1691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 1836 1837 1836 1837 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 2052 2056 2052 2056 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 413 421 <span type="species:ncbi:9606">patients</span>
###xml 1408 1416 <span type="species:ncbi:9606">patients</span>
###xml 1681 1689 <span type="species:ncbi:9606">patients</span>
###xml 2113 2121 <span type="species:ncbi:9606">patients</span>
We have been conducting a series of clinical and/or non-clinical investigations to find an invasive, if possible, noninvasive marker predictive of the differentiation and thereby prognosis of colorectal adenocarcinoma 5-7. The mRNA expression level of vascular endothelial growth factor (VEGF), an endothelial cell-specific mitogen and survival factor, was analyzed using tissue samples obtained from 18 Japanese patients with colorectal adenocarcinoma, and its association with 12 genotypes of VEGF; C-2578A, G-1877A, T-1498C, T-1455C, G-1190A, and G-1154A in the promoter region, C-634G and C-7T in the 5' untranslated region (5'UTR), and C702T, C936T, C1451T, and G1612A in the 3'UTR, were examined. It was concluded that 1) VEGF mRNA expression was up-regulated in colorectal adenocarcinomas compared to adjacent noncancerous colorectal tissues, 2) C-2578A, G-1154A, and G1612A might be associated with a decreased risk of colorectal adenocarcinoma, and 3) T-1498C (in linkage with G-1190A), C-7T, and possibly C-634G, were associated with higher levels of VEGF mRNA in colorectal adenocarcinomas, but not in adjacent noncancerous colorectal tissues 5. In contrast, it was found that 1) mRNA expression of multidrug resistant transporter MDR1/P-glycoprotein, the gene product of MDR1, was down-regulated in colorectal adenocarcinomas compared to adjacent noncancerous colorectal tissues obtained from 21 patients 6, 2) 4 major genetic polymorphisms of MDR1 T-129C in the promoter region, C1236T (silent) in exon 12, G2677A,T in exon 21 resulting in Ala893Thr,Ser, and C3435T (silent) in exon 26 were not associated with disease risk after an analysis of peripheral blood of 48 patients 7, and 3) T-129C was associated with lower levels of MDR1 mRNA both in colorectal adenocarcinomas and in adjacent noncancerous colorectal tissues 6. Taken together, it was suggested that VEGF expression would be linked with MDR1 expression, and their genetic polymorphisms might be promising markers of the prognosis of colorectal adenocarcinoma. In this study, VEGF T-1498C, C-634G, and C-7T were evaluated in 36 Japanese patients with colorectal adenocarcinoma, and their associations with differentiation grade were analyzed. A colorectal cancer cell line, HCT-15, was treated with sodium butyrate (NaB), a typical differentiating agent, and alterations of alkaline phosphatase (ALP) activity, an index of differentiation, and VEGF mRNA expression level were assessed. In addition, the effects of VEGF or MDR1 small interfering RNA (siRNA) on their mRNA expression were assessed.
###end p 8
###begin title 9
2. Materials and Methods
###end title 9
###begin title 10
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 10
###begin p 11
###xml 20 28 <span type="species:ncbi:9606">patients</span>
###xml 102 105 <span type="species:ncbi:9606">men</span>
###xml 113 118 <span type="species:ncbi:9606">women</span>
Thirty-six Japanese patients with colorectal adenocarcinoma diagnosed at Kobe University Hospital (24 men and 12 women) were enrolled in this study. The average age was age 64.6+/-9.3 years ( +/-SD; range, 34-78). A standard treatment protocol was scheduled, and the data on differentiation grade were obtained from medical records. Informed consent was obtained from all subjects prior to their participation in the study, which was approved by the Institutional Review Broad of Kobe University Hospital, Kobe University, Japan.
###end p 11
###begin title 12
VEGF Genotyping
###end title 12
###begin p 13
###xml 73 74 73 74 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</sup>
###xml 160 164 160 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 215 216 215 216 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</sup>
###xml 417 418 417 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 420 424 420 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 464 465 464 465 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</sup>
###xml 700 701 700 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
Genomic DNA was extracted from peripheral blood using a DNeasy Tissue KitR (QIAGEN, Hilden, Germany) according to the manufacturer's directions. In this study, VEGF T-1498C, C-634G and C-7T were determined by TaqManR MGB probe based polymerase chain reaction. The sequences of forward and reverse primers and 2 probes for T-1498C and C-7T, synthesized by Applied Biosystems, Foster City, CA, USA, are listed in Table 1. VEGF C-634G was assessed using a kit (TaqManR SNP Genotyping Assay, part. No. C_8311614_10, Applied Biosystems). The genotypes evaluated were confirmed by direct sequencing using an automatic ABI PRISM 310 Genetic Analyzer (Applied Biosystems) as described in our previous report 5. The primers used for direct sequencing were synthesized by Hokkaido System Science, Co., Ltd. (Sapporo, Japan).
###end p 13
###begin title 14
Effect of NaB on ALP activity and VEGF mRNA expression in HCT-15 cells
###end title 14
###begin p 15
###xml 289 292 289 290 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#174;</sup>
###xml 372 373 370 371 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 416 417 414 415 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 441 443 439 441 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TM</sup>
###xml 528 529 526 527 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 263 269 <span type="species:ncbi:9913">bovine</span>
A colorectal cancer cell line, HCT-15 (passage 43), were purchased from Dainippon Sumitomo Pharma Co., Ltd. (Osaka, Japan). HCT-15 cells were maintained in RPMI1640 culture medium (Invitrogen Corp., Carlsbad, CA, USA) supplemented with heat-inactivated 10% fetal bovine serum (FBS; CELLect(R) GOLD, MP Biomedicals, Irvine, CA, USA). The cells seeded at a density of 3.0x106 cells in 40 ml of culture medium in 175 cm2 culture flasks (NunclonTM, Nalge Nunc International, NY, USA) were grown in an atmosphere of 95% air and 5% CO2 at 37degreesC, and subcultured every 3-4 days using a mixture of 0.02% EDTA and 0.05% trypsin (Invitrogen Corp.).
###end p 15
###begin p 16
###xml 40 42 40 42 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5 </sup>
###xml 100 102 100 102 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TM</sup>
###xml 178 180 178 180 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2 </sub>
###xml 656 657 650 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 734 736 728 730 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TM</sup>
HCT-15 cells seeded at a density of 4x105 cells in 2 ml of culture medium in a 6-well plate (NunclonTM, Nalge Nunc International) were grown in an atmosphere of 95% air and 5% CO2 at 37degreesC. After 24 hrs, the culture medium was replaced, and an aqueous solution of NaB, a typical differentiating agent, was added to give a final concentration of 1 or 5 mM for NaB. The volumetric concentration of purified water was less than 0.1%. After another 24, 48, and 72 hr, the cells were washed twice with ice-cold phosphate buffered saline, and cell pellets were prepared. The expression levels of VEGF mRNA were evaluated as described in our previous report 5. The ALP activity was measured using a commercially available kit (LABOASSAYTM ALP, Wako Pure Chemical Industries, Ltd., Osaka, Japan) in cell lysates prepared with an ultrasonic cell disrupter: the activity was assessed as the rate of conversion from p-nitrophenylphosphate to p-nitrophenol.
###end p 16
###begin title 17
Effect of transfixing VEGF or MDR1 siRNA on mRNA expression in HCT-15 cells
###end title 17
###begin p 18
###xml 52 53 52 53 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 55 56 55 56 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 399 401 399 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 625 627 621 623 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TM</sup>
###xml 680 681 672 673 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</sup>
###xml 804 805 792 793 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</sup>
###xml 1053 1055 1029 1031 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5 </sup>
###xml 1204 1205 1176 1177 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</sup>
The transfection of siRNA was performed as reported 8, 9. siRNA duplexes for VEGF and MDR1 mRNA were synthesized by FASMAC, Co. (Kanagawa, Japan): VEGF (GenBank accession no. NM_001025366): sense (5'-CCA ACA UCA CCA UGC AGA UdTdT-3'), antisense (5'-AUC UGC AUG GUG AUG UUG GdTdT-3'); MDR1 (NM_000927): sense (5'- GGA GGA UUA UGA AGC UAA AdTdT -3'), antisense (5'- UUU AGC UUC AUA AUC CUC CdTdT -3') 10. Scramble siRNA for VEGF and MDR1 was also designed based on the original target sequence: 5'- UAA CAC AGC ACA CCU ACG UdTdT -3' and 5'-AAG AAG GCA UGG UUG UAA AdTdT-3', respectively. A mixture of 8 microl of OligofectamineTM Reagent (Invitrogen Corp.) and 22 microl of Opti-MEMR I Reduced-Serum Medium (Invitrogen Corp.) was incubated at room temperature for 10 min. After that, 360 microL of Opti-MEMR I Reduced-Serum Medium and 10 microl of 20 microM siRNA aqueous solution were added, and the mixture was incubated at room temperature for 20 min, giving 400 microl of siRNA-Oligofectamine complexes. HCT-15 cells were seeded at a density of 1.5x105 cells/well/2 ml in a 6-well plate. After 24 hr, the cells were washed twice with phosphate buffered saline, and supplied with 1600 microl of Opti-MEMR I Reduced-Serum Medium and 400 microl of siRNA-Oligofectamine complexes. This was followed by incubation for 4 hr. The reagents were replaced with RPMI1640 culture medium, and after another 24, 48, and 72 hr, the cells were collected and subjected to assays of the mRNA expression of VEGF or MDR1. The data on cells treated without siRNA were used as a control.
###end p 18
###begin title 19
Statistical analysis
###end title 19
###begin p 20
###xml 498 499 496 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 527 528 525 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">U</italic>
Values are given as the mean +/- standard deviation (SD). The association of VEGF allelic or genotype frequencies with differentiation grade was assessed by the Fisher's exact test. For the data on the effect of NaB, multiple comparisons were performed with an analysis of variance (ANOVA) followed by the Scheffe test, provided the variance was similar. If this was not the case, the Scheffe-type test was performed after the Kruskal-Wallis test. For the data on the effect of siRNA, the unpaired t test or the Mann-Whitney's U test was performed. P values of less than 0.05 were considered significant.
###end p 20
###begin title 21
3. Results and Discussion
###end title 21
###begin p 22
###xml 6 7 6 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">2</xref>
###xml 45 49 45 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 103 107 103 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 476 484 <span type="species:ncbi:9606">patients</span>
Table 2 lists the data on the association of VEGF T-1498C, C-634G and C-7T with differentiation grade. VEGF T-1498C, but not C-634G or C-7T, was suggested to be predictive of poorly-differentiated colorectal adenocarcinomas, and thereby a poor prognosis (p = 0.064 for genotype, p = 0.037 for allele). However, statistical analysis without the data of poorly-differentiated ones resulted in no difference (p = 0.153 for genotype, p = 0.128 for allele). Only a small number of patients enrolled in this study, and further investigations should be addressed to draw a conclusion.
###end p 22
###begin p 23
###xml 83 85 83 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 86 88 86 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 213 215 213 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 216 218 216 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 537 539 537 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 540 542 540 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 742 744 742 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 745 747 745 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 811 813 811 813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 815 817 815 817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 843 847 843 847 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 941 942 941 942 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 963 967 963 967 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 1026 1027 1026 1027 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">2</xref>
###xml 547 555 <span type="species:ncbi:9606">patients</span>
VEGF, first termed vascular permeability factor (VPF), was discovered in the 1980s 11-16. VEGF is now recognized to be a member of the VEGF gene family, and in the new system of nomenclature, is defined as VEGF-A 17-19. VEGF is expected to be involved in the pathogenesis of cancer metastasis, retinopathy, age-related macular degeneration, rheumatoid arthritis, and psoriasis, and clinical observations have confirmed that VEGF expression in solid tumors is predictive of resistance to radiotherapy, chemotherapy, and endocrine therapy 17-19. In patients with colorectal cancer, VEGF expression has been found to be associated with disease progression, microvessel density, venous invasion, lymph node and/or liver metastasis, and prognosis 20-24, although reports have not always provided similar conclusions 25, 26. In our previous report, VEGF T-1498C was found to be linked with higher levels of VEGF mRNA in colorectal adenocarcinomas 5. The association of VEGF T-1498C with poorly-differentiated type as shown in Table 2 can be explained by its effect on VEGF expression, although differentiation grade-dependent VEGF expression was not demonstrated in our samples.
###end p 23
###begin p 24
###xml 4 8 4 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 204 206 204 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 207 209 207 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 343 345 343 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 346 348 346 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 358 360 358 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 370 372 370 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 384 386 384 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 388 390 388 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 534 536 534 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 554 556 554 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 592 594 592 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 800 802 800 802 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 959 961 959 961 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 1064 1065 1064 1065 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">2</xref>
###xml 771 779 <span type="species:ncbi:9606">patients</span>
###xml 1016 1024 <span type="species:ncbi:9606">patients</span>
The VEGF gene is located on chromosome 6p21.3 and comprises a 14-kb coding region with 8 exons and 7 introns, and alternative exon splicing results in the production of 4 major and several minor isoforms 17-19. The genetically controlled variation in the production of VEGF was examined in peripheral blood mononuclear cells (PBMCs) or plasma 27-30. C-2578A 28, G-1154A 28, and C936T 29, 30 were found to result in lower levels of VEGF production, and have recently been suggested to be associated with a reduce risk of breast cancer 30, prostate cancer 31, and cutaneous malignant melanomas 32. Compared with C-2578A, G-1154A and C936T, little information is available for T-1498C. In Japanese, the TT/TC/CC ratio was reported to be 44.1%/48.3%/7.6% for type 2 diabetic patients without retinopathy 33, and to our knowledge, no information was presented for healthy subjects, and T-1498C was expected to be less frequently found in Japanese than other races 27. The TT/TC/CC ratio was 44.4%/38.9%/16.7% in Japanese patients with colorectal adenocarcinomas (Table 2), and T-1498C would not be a marker of susceptibility.
###end p 24
###begin p 25
###xml 12 16 12 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR1</italic>
###xml 185 186 185 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 317 318 317 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 522 523 522 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 545 547 545 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
###xml 806 810 806 810 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR1</italic>
###xml 920 921 920 921 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 1050 1052 1050 1052 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B35">35</xref>
###xml 1053 1055 1053 1055 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B40">40</xref>
###xml 1684 1686 1684 1686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B41">41</xref>
###xml 2034 2036 2034 2036 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B42">42</xref>
###xml 2038 2040 2038 2040 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B43">43</xref>
###xml 2273 2274 2273 2274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 2415 2417 2415 2417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B44">44</xref>
###xml 2466 2468 2466 2468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B45">45</xref>
###xml 2557 2559 2557 2559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B46">46</xref>
###xml 2627 2629 2627 2629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B47">47</xref>
###xml 2631 2633 2631 2633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B48">48</xref>
###xml 2830 2834 2830 2834 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR1</italic>
###xml 682 690 <span type="species:ncbi:9606">patients</span>
###xml 1163 1168 <span type="species:ncbi:9606">Human</span>
###xml 1904 1909 <span type="species:ncbi:9606">human</span>
###xml 2380 2388 <span type="species:ncbi:9606">patients</span>
###xml 2431 2439 <span type="species:ncbi:9606">patients</span>
###xml 2517 2525 <span type="species:ncbi:9606">patients</span>
Previously, MDR1 T-129C, but not G2677A,T or C3435T, was found to result in lower levels of MDR1 mRNA both in colorectal adenocarcinomas and in adjacent noncancerous colorectal tissues 6. Relatively weak expression was suggested in moderately-differentiated compared to well-differentiated colorectal adenocarcinomas 6. No significant association was observed for the dependency of grade of differentiation on MDR1 expression, presumably because poorly-differentiated colorectal adenocarcinomas are infrequent in Japanese 6, but Potocnik et al. 34 indicated lower levels of MDR1 expression in poorly-differentiated than well-differentiated colorectal cancers obtained from Slovenia patients, with intermediate levels of expression for moderately-differentiated cancers. Collectively, it was concluded that MDR1 T-129C might be predictive of poorly-differentiated colorectal adenocarcinomas, and thereby a poor prognosis 6. MDR1 is a glycosylated membrane protein of 170 kDa, belonging to the ATP-binding cassette superfamily of membrane transporters 35-40. MDR1 was originally isolated from resistant tumor cells as part of the mechanism of multidrug resistance. Human MDR1 has been found to be expressed throughout the body to confer intrinsic resistance to the tissues by exporting unnecessary or toxic exogenous substances or metabolites. Recent investigations have challenged the notion that MDR1 has evolved merely to facilitate the efflux of xenobiotics and have raised the possibility that MDR1 plays a fundamental role in regulating apoptosis. Given the down-regulation of MDR1 expression during the differentiation of pluripotent stem cells along the myeloid lineage in 1991 41, its potential implications in cell systems resulting in cell death or differentiation have been discussed for the last decade. Recently, we and Goto et al. have found that MDR1 mRNA expression is down-regulated in a human colon carcinoma cell line, Caco-2, prior to the up-regulation of the expression of villin mRNA, a marker of differentiation 42, 43. A lower level of MDR1 mRNA in adenocarcinomas than adjacent noncancerous tissues suggests its down-regulation as a consequence of the malignant transformation of colorectal tissues, possibly with the suppression of differentiation 6. Lower levels of MDR1 in cancerous tissues than the adjacent normal tissues were also reported in French patients with renal cell carcinoma 44 and Japanese patients with colorectal carcinoma 45, but the opposite result was obtained in French patients with advanced breast carcinoma 46. Poorly-differentiated types are found in 13.8-17.5% of Caucasians 47, 48, more frequent than in Japanese, suggesting a difference in the nature of the cancer between Caucasians and Japanese. Further clinical investigations might be needed to conclude the usefulness of MDR1 T-129C with regards to predictions of prognosis.
###end p 25
###begin p 26
###xml 195 196 195 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 198 199 198 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 206 207 206 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1</xref>
###xml 536 537 536 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 544 545 544 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">2</xref>
###xml 839 840 839 840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">3</xref>
###xml 1397 1402 1397 1402 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vinca</italic>
###xml 1502 1504 1502 1504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B35">35</xref>
###xml 1505 1507 1505 1507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B40">40</xref>
###xml 1287 1295 <span type="species:ncbi:9606">patients</span>
Compared with adjacent noncancerous colorectal tissues, VEGF mRNA expression was up-regulated, but MDR1 mRNA expression was down-regulated in colorectal adenocarcinomas, suggesting their linkage 5, 6. Fig. 1 shows the effect of NaB on ALP activity and VEGF mRNA expression in HCT-15 cells. ALP activity increased in a NaB-concentration and treatment time-dependent manner, and VEGF mRNA expression was suppressed as ALP activity increased. In our previous report, treatment with NaB resulted in an up-regulation of MDR1 mRNA expression 6. Fig. 2 shows the effects of transfecting VEGF siRNA on the mRNA expression of VEGF and MDR1 in HCT-15 cells. VEGF mRNA expression was suppressed; indicating a successful transfection of VEGF siRNA, and under these conditions, MDR1 mRNA expression was increased to 288-332% of the control level. Fig. 3 shows the effects of transfecting MDR1 siRNA on the mRNA expression of VEGF and MDR1. MDR1 mRNA expression was suppressed, but VEGF mRNA expression was not altered. It should be that scramble siRNA for VEGF and MDR1 had no effect on the expression of either mRNA (data not shown). Taken together, it could be said that VEGF itself or the factors resulting in production of VEGF had a suppressive effect on MDR1 expression, suggesting that cancer patients with a higher VEGF expression will show a relatively high sensitivity for MDR1 substrates, including vinca-alkaloids, anthracyclines and taxanes. Considering that a number of factors affect MDR1 expression 35-40, VEGF expression and/or genetic polymorphisms of VEGF were thought to be superior.
###end p 26
###begin p 27
###xml 12 16 12 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 314 318 314 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR1</italic>
###xml 418 422 418 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 522 530 <span type="species:ncbi:9606">patients</span>
In summary, VEGF T-1498C, but not C-634G or C-7T, was predictive of poorly-differentiated colorectal adenocarcinomas, and thereby a poor prognosis. This effect can be explained by that on VEGF expression. In vitro experiments using HCT-15 cells have suggested that VEGF expression was linked with MDR1 expression. MDR1 T-129C was also reported to be predictive of poorly-differentiated colorectal adenocarcinomas, and VEGF T-1498C polymorphism is also a candidate marker, but further investigations with a large number of patients should be addressed to draw a conclusion.
###end p 27
###begin p 28
This work was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan, and by a research grant from Uehara Memorial Foundation, Japan.
###end p 28
###begin article-title 29
Pathologic prognostic factors for gastrointestinal cancer
###end article-title 29
###begin article-title 30
Improved prognosis of solid-type poorly differentiated colorectal adenocarcinoma: a clinicopathological and immunohistochemical study
###end article-title 30
###begin article-title 31
Clinicopathological characteristics of poorly differentiated adenocarcinoma of the colon and rectum
###end article-title 31
###begin article-title 32
Expression of differentiation-related genes in colorectal cancer: possible implications for prognosis
###end article-title 32
###begin article-title 33
Association of VEGF genotype with mRNA level in colorectal adenocarcinomas
###end article-title 33
###begin article-title 34
MDR1 T-129C polymorphism can be predictive of differentiation, and thereby prognosis of colorectal adenocarcinomas in Japanese
###end article-title 34
###begin article-title 35
###xml 70 78 <span type="species:ncbi:9606">patients</span>
MDR1 haplotype frequencies in Japanese and Caucasian, and in Japanese patients with colorectal cancer and esophageal cancer
###end article-title 35
###begin article-title 36
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
###end article-title 36
###begin article-title 37
Identification of essential genes in cultured mammalian cells using small interfering RNAs
###end article-title 37
###begin article-title 38
Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi)
###end article-title 38
###begin article-title 39
Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid
###end article-title 39
###begin article-title 40
Further characterization of malignant glioma-derived vascular permeability factor
###end article-title 40
###begin article-title 41
Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells
###end article-title 41
###begin article-title 42
Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis
###end article-title 42
###begin article-title 43
Vascular endothelial growth factor is a secreted angiogenic mitogen
###end article-title 43
###begin article-title 44
Vascular permeability factor, an endothelial cell mitogen related to PDGF
###end article-title 44
###begin article-title 45
Role of vascular endothelial growth factor in regulation of physiological angiogenes
###end article-title 45
###begin article-title 46
Regulation of vascular permeability by vascular endothelial growth factors
###end article-title 46
###begin article-title 47
Vascular endothelial growth factor as a target for anticancer therapy
###end article-title 47
###begin article-title 48
Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in colorectal cancer
###end article-title 48
###begin article-title 49
###xml 93 98 <span type="species:ncbi:9606">human</span>
Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer
###end article-title 49
###begin article-title 50
Vascular endothelial growth factor is up-regulated in the early pre-malignant stage of colorectal tumour progression
###end article-title 50
###begin article-title 51
###xml 160 165 <span type="species:ncbi:9606">human</span>
Expression of vascular endothelial growth factor and its receptor KDR (kinase domain-containing receptor)/Flk-1 (fetal liver kinase-1) as prognostic factors in human colorectal cancer
###end article-title 51
###begin article-title 52
###xml 111 116 <span type="species:ncbi:9606">human</span>
Expression analysis of vascular endothelial growth factors and their relationships to lymph node metastasis in human colorectal cancer
###end article-title 52
###begin article-title 53
###xml 76 81 <span type="species:ncbi:9606">human</span>
Microvessel morphology and vascular endothelial growth factor expression in human colonic carcinoma with or without metastasis
###end article-title 53
###begin article-title 54
Clinical significance of vascular endothelial growth factor expression and neovascularization in colorectal carcinoma
###end article-title 54
###begin article-title 55
Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production
###end article-title 55
###begin article-title 56
Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection
###end article-title 56
###begin article-title 57
A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels
###end article-title 57
###begin article-title 58
A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk
###end article-title 58
###begin article-title 59
Influence of cytokine gene polymorphisms on the development of prostate cancer
###end article-title 59
###begin article-title 60
Influence of vascular endothelial growth factor single nucleotide polymorphisms on tumour development in cutaneous malignant melanoma
###end article-title 60
###begin article-title 61
A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes
###end article-title 61
###begin article-title 62
Naturally occurring mutations and functional polymorphisms in multidrug resistance 1 gene: correlation with microsatellite instability and lymphoid infiltration in colorectal cancers
###end article-title 62
###begin article-title 63
MDR1 genotype-related pharmacokinetics and pharmacodynamics
###end article-title 63
###begin article-title 64
Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs
###end article-title 64
###begin article-title 65
Pharmacogenetics of drug transporters and its impact on the pharmacotherapy
###end article-title 65
###begin article-title 66
Pharmacogenomics of MDR and MRP subfamilies
###end article-title 66
###begin article-title 67
MDR1 genotype-related pharmacokinetics: fact or fiction?
###end article-title 67
###begin article-title 68
An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy
###end article-title 68
###begin article-title 69
###xml 71 76 <span type="species:ncbi:9606">human</span>
Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells
###end article-title 69
###begin article-title 70
MDR1 up-regulated by apoptotic stimuli suppresses apoptotic signaling
###end article-title 70
###begin article-title 71
###xml 69 74 <span type="species:ncbi:9606">human</span>
Decreased expression of P-glycoprotein during differentiation in the human intestinal cell line Caco-2
###end article-title 71
###begin article-title 72
Expression of genes involved in chemoresistance, proliferation and apoptosis in clinical samples of renal cell carcinoma and correlation with clinical outcome
###end article-title 72
###begin article-title 73
###xml 108 113 <span type="species:ncbi:9606">human</span>
Increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas
###end article-title 73
###begin article-title 74
Enhancement of mdr1 gene expression in normal tissue adjacent to advanced breast cancer
###end article-title 74
###begin article-title 75
Histopathological grade, mucinous differentiation and DNA ploidy in relation to prognosis in colorectal carcinoma
###end article-title 75
###begin article-title 76
Colorectal carcinoma: evaluation of histologic grade and factors influencing prognosis
###end article-title 76
###begin p 77
Effect of NaB on ALP activity and VEGF mRNA expression in HCT-15 cells. HCT-15 cells were treated with 1 or 5 mM NaB for 24, 48, and 72 hr, and ALP activity and VEGF mRNA levels were assessed. The results were expressed as the mean +/- SD of 4 independent experiments. (A) ALP activity, (B) VEGF mRNA. Open column: control (0 mM NaB), closed column: 1 mM NaB, hatched column: 5 mM NaB. *: p < 0.05, when compared with the control experiment.
###end p 77
###begin p 78
Effect of VEGF siRNA on mRNA expression of VEGF and MDR1 in HCT-15 cells. HCT-15 cells were treated with VEGF siRNA for 24, 48, and 72 hrs, and mRNA expression levels of VEGF and MDR1 were assessed. The results were expressed as the mean +/- SD of 3-4 independent experiments. (A) VEGF mRNA, (B) MDR1 mRNA. Open column: without VEGF siRNA, closed column: with VEGF siRNA. The scramble siRNA for VEGF had no effect on the mRNA expression of VEGF or MDR1. *: p < 0.05, when compared with no VEGF siRNA.
###end p 78
###begin p 79
Effect of MDR1 siRNA on mRNA expression of VEGF and MDR1 in HCT-15 cells. HCT-15 cells were treated with MDR1 siRNA for 24, 48, and 72 hr, and mRNA expression levels of VEGF and MDR1 were assessed. The results were expressed as the mean +/- SD of 3-4 independent experiments. (A) VEGF mRNA, (B) MDR1 mRNA. Open column: without MDR1 siRNA, closed column: with MDR1 siRNA. The scramble siRNA for MDR1 had no effect on the mRNA expression of VEGF or MDR1. *: p < 0.05, when compared with no MDR1 siRNA.
###end p 79
###begin p 80
###xml 41 45 41 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
Sequences of primers and probes used for VEGF T-1498C and C-7T genotyping
###end p 80
###begin p 81
###xml 15 19 15 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
Association of VEGF T-1498C, C-634G, and C-7T with differentiation grade of colorectal adenocarcinomas in Japanese
###end p 81

